Hybrigenics, a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has hired William Vickery as Head of Corporate and Business Development, a newly created position.
William worked for five years at ExonHit Therapeutics as Senior Director of Business Development. During this time, he negotiated multiple extensions to ExonHit Therapeutics’ strategic partnership with Allergan, secured it’s participation in PharmaCog (the European Innovative Medicines Initiative consortium on Alzheimer’s disease) and in-licensed a breast cancer diagnostic discovered by Gustave Roussy Institute.
Prior to joining ExonHit Therapeutics in 2006 and since 2003, William served as a Business Development Director of Roche Pharmaceuticals in the US. During his tenure, he was responsible for out-licensing and divestiture of Roche-developed assets. He led the Roche strategic alliance teams which established the alliances with Syrrx and Amira. From 2000 to 2003, he held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases. He received an MBA from INSEAD and an engineering degree from HEI (Lille, France).
“I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,” said William Vickery, Hybrigenics’ new Head of Corporate and Business Development.
“The addition of William Vickery to our management line-up is key to implementing our top priority strategy which is now focused on partnering inecalcitol for further clinical co-development in prostate cancer. His experience and track record both in pharma and biotech organizations will be extremely valuable,” said Remi Delansorne, Hybrigenics’ CEO.]
Hybrigenics SA
